LAMEA Insulin Syringes Market (2021 to 2027) - Size, Share & Industry Trends Analysis Report

·6 min read
Company Logo
Company Logo

Dublin, May 18, 2022 (GLOBE NEWSWIRE) -- The "LAMEA Insulin Syringes Market Size, By Disease (Type 2 Diabetes and Type 1 Diabetes), By Syringe Size, By End User, By Country and Growth Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The Latin America, Middle East and Africa Insulin Syringes Market is expected to witness market growth of 8.1% CAGR during the forecast period (2021-2027).

The insulin dosage determines the appropriate syringe size for individuals. One may need various syringe sizes to modify your insulin dose as needed because the insulin dose may alter based on the blood sugar levels. Insulin needles are available in a variety of diameters and thicknesses.

The length of a needle controls how far it can penetrate your skin. Insulin needles should only penetrate just beneath the skin, not into muscle. Shorter needles are less likely to penetrate the muscle. Insulin is administered subcutaneously, or beneath the skin, into the fat layer. A short needle is utilized to inject insulin into the fatty layer between the muscle andskin in this sort of injection.

Obesity rates among children and adolescents in Gulf countries range from 5% to 14% for men and 3% to 18% for girls. Obesity is on the rise in the Gulf area, with prevalence rates ranging from 2 percent to 55 percent in adult females and 1 percent to 30 percent in adult males. Obesity in the UAE is twice as high as the worldwide norm; in Kuwait, more than half of the adult population has diabetes connected to obesity, and 75 percent of Egyptians are overweight; medical experts blame the desert environment.

The Brazil market dominated the LAMEA Insulin Syringes Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $44.5 million by 2027. The Argentina market is expected to exhibit a CAGR of 8.6% during (2021 - 2027). Additionally, The UAE market is poised to grow a CAGR of 7.8% during (2021 - 2027).

Based on Disease, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Syringe Size, the market is segmented into 3/10 CC Syringe (0.3ml), 1/2 CC Syringe (0.5ml), 1CC Syringe (1ml) and Others. Based on End User, the market is segmented into Hospitals & Clinics, Homecare Settings, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Hindustan Syringes & Medical Devices Ltd., Novo Nordisk A/S, Biocon Limited, Eli Lilly and Company, Abbott Laboratories, Becton, Dickinson and Company, Cardinal Health, Inc., Medline Industries, Inc., Terumo Corporation, and Nipro Corporation.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. LAMEA Insulin Syringes Market by Disease
3.1 LAMEA Type 2 Diabetes Market by Country
3.2 LAMEA Type 1 Diabetes Market by Country

Chapter 4. LAMEA Insulin Syringes Market by Syringe Size
4.1 LAMEA 3/10 CC Syringe (0.3ml) Market by Country
4.2 LAMEA 1/2 CC Syringe (0.5ml) Market by Country
4.3 LAMEA 1CC Syringe (1ml) Market by Country
4.4 LAMEA Other Syringe Size Market by Country

Chapter 5. LAMEA Insulin Syringes Market by End User
5.1 LAMEA Hospitals & Clinics Market by Country
5.2 LAMEA Homecare Settings Market by Country
5.3 LAMEA Others Market by Country

Chapter 6. LAMEA Insulin Syringes Market by Country
6.1 Brazil Insulin Syringes Market
6.1.1 Brazil Insulin Syringes Market by Disease
6.1.2 Brazil Insulin Syringes Market by Syringe Size
6.1.3 Brazil Insulin Syringes Market by End User
6.2 Argentina Insulin Syringes Market
6.2.1 Argentina Insulin Syringes Market by Disease
6.2.2 Argentina Insulin Syringes Market by Syringe Size
6.2.3 Argentina Insulin Syringes Market by End User
6.3 UAE Insulin Syringes Market
6.3.1 UAE Insulin Syringes Market by Disease
6.3.2 UAE Insulin Syringes Market by Syringe Size
6.3.3 UAE Insulin Syringes Market by End User
6.4 Saudi Arabia Insulin Syringes Market
6.4.1 Saudi Arabia Insulin Syringes Market by Disease
6.4.2 Saudi Arabia Insulin Syringes Market by Syringe Size
6.4.3 Saudi Arabia Insulin Syringes Market by End User
6.5 South Africa Insulin Syringes Market
6.5.1 South Africa Insulin Syringes Market by Disease
6.5.2 South Africa Insulin Syringes Market by Syringe Size
6.5.3 South Africa Insulin Syringes Market by End User
6.6 Nigeria Insulin Syringes Market
6.6.1 Nigeria Insulin Syringes Market by Disease
6.6.2 Nigeria Insulin Syringes Market by Syringe Size
6.6.3 Nigeria Insulin Syringes Market by End User
6.7 Rest of LAMEA Insulin Syringes Market
6.7.1 Rest of LAMEA Insulin Syringes Market by Disease
6.7.2 Rest of LAMEA Insulin Syringes Market by Syringe Size
6.7.3 Rest of LAMEA Insulin Syringes Market by End User

Chapter 7. Company Profiles
7.1 Hindustan Syringes & Medical Devices Ltd.
7.1.1 Company Overview
7.2 Novo Nordisk A/S
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental & Regional Analysis
7.2.4 Research & Development Expenses
7.2.1 Recent strategies and developments:
7.2.1.1 Acquisitions and Mergers:
7.3 Biocon Limited
7.3.1 Company Overview
7.3.2 Recent strategies and developments:
7.4 Eli Lilly and Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent Strategies and Developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Product Launches and Product Expansions:
7.4.5.3 Approvals and Trials:
7.5 Abbott Laboratories
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Becton, Dickinson and Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.9 Terumo Corporation
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.10. Nipro Corporation
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expenses

For more information about this report visit https://www.researchandmarkets.com/r/o3imf8

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting